Details for Patent: 9,700,537
✉ Email this page to a colleague
Which drugs does patent 9,700,537 protect, and when does it expire?
Patent 9,700,537 protects VASCEPA and is included in one NDA.
This patent has nine patent family members in six countries.
Summary for Patent: 9,700,537
| Title: | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
| Abstract: | Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient. |
| Inventor(s): | Yokoyama; Mitsuhiro (Kobe, JP), Origasa; Hideki (Toyama, JP), Matsuzaki; Masunori (Ube, JP), Matsuzawa; Yuji (Takarzuka, JP), Saito; Yasushi (Chiba, JP) |
| Assignee: | MOCHIDA PHARMACEUTICAL CO., LTD. (Tokyo, JP) |
| Application Number: | 15/431,958 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,700,537 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,700,537
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA | ⤷ Sign Up | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-002 | Feb 16, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,700,537
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2006-152740 | May 31, 2006 |
International Family Members for US Patent 9,700,537
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2022495 | ⤷ Sign Up | 122021000058 | Germany | ⤷ Sign Up |
| European Patent Office | 2022495 | ⤷ Sign Up | 132021000000154 | Italy | ⤷ Sign Up |
| European Patent Office | 2022495 | ⤷ Sign Up | C202130051 | Spain | ⤷ Sign Up |
| European Patent Office | 2022495 | ⤷ Sign Up | 21C1045 | France | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
